Another systemic review has demonstrated that patients with RA who are treated with TNF inhibitors, such as infliximab or adalimumab, have a higher incidence of developing ATAs compared to those with other inflammatory conditions like Crohn’s disease (13). Here, TNF is linked to rheumatoid arthritis.